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Abstract
Background: There is growing evidence that the intrauterine environment can impact the neurodevelopment of the fetus
through alterations in the functional epigenome of the placenta. In the placenta, the HSD11B2 gene encoding the 11-beta
hydroxysteroid dehydrogenase enzyme, which is responsible for the inactivation of maternal cortisol, is regulated by DNA
methylation, and has been shown to be susceptible to stressors from the maternal environment.
Methodology/Principal Findings: We examined the association between DNA methylation of the HSD11B2 promoter
region in the placenta of 185 healthy newborn infants and infant and maternal characteristics, as well as the association
between this epigenetic variability and newborn neurobehavioral outcome assessed with the NICU Network
Neurobehavioral Scales. Controlling for confounders, HSD11B2 methylation extent is greatest in infants with the lowest
birthweights (P=0.04), and this increasing methylation was associated with reduced scores of quality of movement
(P=0.04).
Conclusions/Significance: These results suggest that factors in the intrauterine environment which contribute to birth
outcome may be associated with placental methylation of the HSD11B2 gene and that this epigenetic alteration is in turn
associated with a prospectively predictive early neurobehavioral outcome, suggesting in some part a mechanism for the
developmental origins of infant neurological health.
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Introduction
The period of intrauterine development is recognized as a
critical period during which the environment experienced by the
mother and developing fetus can have profound effects on the later
health of the infant. While the epidemiologic data is clear, the
molecular basis of these effects remain to be elucidated, although
epigenetic regulation likely plays a central role as a mediator of this
fetal programming of adult health. These mechanisms, which
include processes such as DNA methylation and post-translational
modification of histones can be passed on through cell division and
are thus considered stable mechanisms of maintaining cellular
control, in a tissue-specific pattern, throughout life. Evidence is
accumulating that these epigenetic mechanisms are susceptible to
environmental signals, and can be altered, particularly at critical
periods of development [1].
Much of the literature on the developmental origins of health
and disease has focused on the relationship between growth, as
reflected by infant birth weight, and its association with
cardiovascular and metabolic outcomes [2,3,4]. Yet, the effects
of epigenetic changes are not limited to metabolic outcomes, and
infant growth has now been linked to various neurodevelopmental
and mental health outcomes including schizophrenia [5],
depression [6,7,8], and psychological distress [9,10,11]. Birth
weight itself does not likely lead directly to these outcomes, but
instead represents an integrated reflection of the in utero period
and the environment experienced by the developing fetus [12].
The environment experienced by the fetus is regulated by the
placenta, which plays an active immune-endocrine functional role
in pregnancy, in addition to its role in nutrient, gas, and waste
exchange. Rapid advancements in the discovery of the integrated
regulation of neuropeptide homeostasis within and outside the
brain as well as placenta [13,14,15] has led to the formulation of a
new concept that the placenta is the ‘‘third brain’’ that links the
developed (maternal) and developing (fetal) brains [14]. We have
expanded this concept to understanding of the pathophysiology of
intrauterine insults [16]. Specifically, the placenta plays a key role
in the appropriate development of the HPA axis, and we have
PLoS ONE | www.plosone.org 1 March 2012 | Volume 7 | Issue 3 | e33794shown that stress factors during pregnancy, resulting from various
adverse intrauterine environments, are associated with epigenetic
alterations leading to reduced placental 11beta-hydroxysteroid
dehydrogenase type 2 (HSD11B2) and norepinephrine transporter
(NET) gene expression resulting in increased circulating catechol-
amine levels in the fetus and placental microenvironment,
increased fetal exposure to cortisol, and dysregulation of the
infant’s HPA axis and neurobehavior [16,17]. In this study, we are
specifically asking how measures of infant growth are associated
with functional epigenetic alterations in the placental HSD11B2
gene promoter, and if epigenetic alterations to this gene are
associated with prospective, validated neurobehavioral profiles.
Results
The demographics of the 186 infants in our population that
were studied are provided in Table 1. Based on the intended
composition of the cohort, the population is over-represented by
small and large for gestational age infants (SGA and LGA,
respectively). All infants enrolled were considered at or near term,
with a mean gestational age of 39.1 weeks. The racial profile of our
population is mixed, with 10% of mothers reporting an African-
American race, and over 20% a race other than caucasian or
African American. Only 4% of participants reported smoking
tobacco during pregnancy, and less than 1% reported alcohol or
Table 1. Population Demographics, Clinical Characteristics, and NNNS Summary Scores.
N % Mean Std. Dev. Median Min Max
Categorical Variables
Growth Status
SGA 53 28
AGA 100 54
LGA 33 18
Infant Gender
Female 101 55
Male 84 45
Maternal Race
Caucasian 124 67
African American 19 10
Other 39 21
Unknown 4 2
Maternal Insurance
Public 101 54
Private 85 46
Maternal Tobacco Use During Pregnancy
No 176 95
Yes 8 4
Unknown 2 1
Continuous Variables
Birth weight (g) 186 3240.8 685.1 3132.5 1705 4730
Gestational Age (weeks) 186 39.1 1.1 39.2 37.0 41.2
Maternal Age (yrs) 186 28.3 5.8 29.0 18.0 40.0
Habituation 98 7.0 1.5 7.3 1.0 9.0
Attention 160 4.1 1.2 4.1 1.6 7.6
Stress Abstinence 186 0.21 0.07 0.20 0.06 0.41
Quality of Movement 186 4.0 0.69 4.1 2.2 5.5
Excitability 186 4.7 3.0 5 0 13
Handling 186 0.37 0.24 0.38 0.0 1.0
Self-regulation 185 4.7 0.9 4.6 2.3 7.0
Arousal 186 4.1 0.9 4.1 1.9 6.3
Hypertonicity 186 0.33 0.73 0 0 5
Hypotonicity 186 0.61 0.98 0 0 7
Asymmetrical Reflexes 186 2.0 1.4 2 0 7
Lethargy 186 6.2 2.7 6 1 14
Non-optimal Reflexes 186 6.4 2.2 7 0 11
Note: Not all N values equal 186 because of missing values.
doi:10.1371/journal.pone.0033794.t001
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characteristics of the population is also mixed, with 54% of the
population utilizing public health insurance. Also included in
Table 1 are the descriptive statistics of the summary scores for the
10 NNNS measures examined in this study.
Quantitative bisulfite pyrosequencing was used to determine the
DNA methylation status of a CpG island region in the promoter of
the HSD11B2 gene previously shown to exhibit differential
methylation in human placenta tissue in our sample of 186
placentas [18]. To determine the functional significance of the
variation in methylation in these samples, we also performed gene
expression analysis using qRT-PCR in a subset of 95 placentas
examined. A moderate, statistically significant negative correlation
(r=20.24, P,0.02) was observed between mean extent of
HSD11B2 methylation across the 4 CpG loci examined and
mRNA expression of HSD11B2 (Figure 1). We have previously
demonstrated a relationship between infant birth weight status and
DNA methylation of the glucocorticoid receptor promoter [19]
and so examined the association between various measures of
infant growth and maternal and infant clinical characteristics and
overall mean methylation of the HSD11B2 gene promoter region.
Figure 2 presents the bivariate correlations between mean extent
of HSD11B2 methylation and each of these characteristics.
Moderate, statistically significant negative, correlations were
observed between infant birthweight, and ponderal index (ratio
of weight for length) and HSD11B2 methylation, demonstrating
smaller and leaner/thinner infants had increased levels of
HSD11B2 methylation. This was clearly shown by comparison of
the extent of HSD11B2 methylation in intrauterine growth
restricted vs. non-IUGR infants, where IUGR infants demon-
strated a significantly greater extent of HSD11B2 methylation
(P=0.007, Figure 2F). More modest, yet statistically significant
negative correlations were observed between HSD11B2 methyl-
ation extent and infant length and gestational age.
The relationship between these measures of growth and
HSD11B2 methylation extent, controlled for infant gender,
maternal age, and gestational age are provided in Table 2. There
is a consistent negative association between birthweight, ponderal
index and gestational age and the extent of methylation in the
HSD11B2 promoter, but the association between infant length and
methylation is attenuated in these adjusted models. The
relationship is particularly strong, consistent with the bivariate
tests, between IUGR status and methylation. Taken together,
these results demonstrate that specific measures of intrauterine
growth are associated with DNA methylation of this gene in the
placenta.
The relationship between mean methylation extent of the
HSD11B2 gene promoter and each of the individual NNNS
summary scores was examined using a Spearman rank correlation,
the results of which are tabulated in Table 3. Infant quality of
movement scores showed a significant negative correlation,
suggesting that increased HSD11B2 methylation was associated
with poorer quality of movement (r=20.18, P=0.01). Infant
hypertonicity also showed a negative trend in its association with
HSD11B2 methylation (r=20.11, P=0.06), while infant atten-
tion showed a positive trend in its association with HSD11B2
methylation, with increasing methylation related to increasing
infant attention scores (r=0.14, P=0.08). Figure 3 depicts these
relationships. The other scores were not associated with HSD11B2
methylation at the P,0.1 level.
To examine if the association between NNNS outcomes and
HSD11B2 methylation was independent of infant growth, gender,
and maternal age, we utilized multivariable generalized linear
regression to model NNNS outcomes (quality of movement,
hypertonicity, and attention) with HSD11B2 methylation alone, or
controlling for these additional factors. The results of these models
including the effect sizes (ß values) and statistical significance are
shown in Table 4. As expected from the univariate correlation
analyses, in the unadjusted model, an increase in methylation of 10
fold (i.e. 1 log) of the HSD11B2 promoter region was significantly
associated with a decrease in infant quality of movement of 1.3
units. Controlling for infant growth, gender, and maternal age
attenuated slightly the effect, of HSD11B2 methylation on quality
of movement, with a 10-fold increase of methylation now
associated with a significant decrease in quality of movement of
1.2 units, independent of growth, gender and maternal age.
Interestingly, each year of maternal age was associated with a
small but significant increase in quality of movement independent
of the other factors. On the other hand, a 10-fold increase in
methylation showed a trend for an increase in infant attention
score of 1.89 units, which was attenuated and not significant when
controlled for infant growth, as well as infant gender and maternal
age. Hypertonicity decreased by nearly 1 unit with a 10-fold
increase in HSD11B2 methylation, a result that also was
attenuated and not significant when confounders were included
in the model.
Discussion
Alteration to the placental expression of genes involved in the
HPA axis, including those involved in cortisol metabolism have
been linked to stresses during the intrauterine period and to
adverse pregnancy outcomes [16,17,20,21]. This study was aimed
at addressing if and how epigenetic regulation of the HSD11B2
gene, a key gene involved in cortisol regulation in the placenta, is
related to infant growth and to prospectively validated neurobe-
havioral outcomes in newborns. We have demonstrated an inverse
association between measures of intrauterine growth, including
birth weight and ponderal index with the extent of DNA
methylation of the HSD11B2 gene promoter. Growth restricted
infants, and particularly those with clinically diagnosed intrauter-
Figure 1. Scatterplot of the correlation between mean HSD11B2
methylation extent and normalized HSD11B2 mRNA expres-
sion. The Spearman correlation coefficient (r) and associated P-value
provided.
doi:10.1371/journal.pone.0033794.g001
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tion than their appropriately grown counterparts. We also
identified a significant inverse relationship between the extent of
HSD11B2 methylation and infant quality of movement. There was
also a trend toward a positive correlation between HSD11B2
methylation and infant attention.
In both animal models and human studies, maternal stress,
defined broadly to include illicit drug exposures, tobacco smoking,
anxiety, and depression, and their accompanying physiologic
responses has been linked to the downregulation of placental
HSD11B2 gene expression, and accompanying increased fetal
exposure to cortisol [16,17,22,23,24,25]. In turn, this downregu-
lation of HSD11B2 has been linked to growth restriction in rats
[26], and humans [27,28]. We have previously observed that the
glucocorticoid receptor also undergoes functional DNA methyla-
tion resulting in reduced expression in the placenta, but found the
lowest levels of methylation of this receptor in SGA infants [19].
This might suggest that an adverse intrauterine environment
leading to growth restriction may enhance infant cortisol exposure
and its downstream effects both by reducing HSD11B2 expression
and by allowing glucocorticoid receptor expression by maintaining
low levels of methylation at that promoter. The enhanced levels of
Figure 2. Plots of the correlations between HSD11B2 mean methylation extent and infant characteristics. Scatterplots depict the
correlation of HSD11B2 mean methylation extent (y-axis) and (A) infant birthweight in g, (B) infant length in cm, (C) infant gestational age in weeks,
and (D) infant ponderal index in g/cm
36100 on the x-axes, with the Spearman correlation coefficient (r) and associated P-value provided. Boxplots
representing HSD11B2 mean methylation extent (y-axis) by (E) growth category (small for gestational age=SGA, appropriate for gestational
age=AGA, large for gestational age=LGA) and (F) clinical intrauterine growth restriction (IUGR) diagnosis (x-axes). Width of box is proportional to
square root of n within each group, with the median depicted as the thick horizontal line centered in the box, the 25
th and 75
th percentiles as the
outer edges of the box, and the 5
th and 95
th percentiles the whiskers. P-values represent the results of a non-parametric Kruskal-Wallis Test (E) and
Mann-Whitney U-test (F).
doi:10.1371/journal.pone.0033794.g002
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responsible for inappropriate programming of the HPA axis
[29,30] as well as altered neuromuscular development in the infant
[31,32], demonstrated by our findings with infant quality of
movement.
Animal models have also linked reduced HSD11B2 gene
expression to adverse neurobehavioral outcomes including in-
creased anxiety and stress in adult rodents [33,34,35]. In humans,
increased cortisol levels at particular periods of pregnancy, in a
sexually dimorphic manner, have been linked to reduced infant
neuromuscular maturation [31]. Consistent with the concept of
‘‘critical developmental periods,’’ neonatal treatment of premature
infants with exogenous glucocorticoids has recently been linked to
adverse neurodevelopmental outcomes [36] while this effect may
be confounded by many additional factors [37]. Our data suggest
that epigenetic regulation of HSD11B2 gene expression is
associated with alterations of the maternal environment which
affect intrauterine growth. These alterations in turn, play a role in
neurobehavioral development, particularly with neuromuscular
development measured as quality of movement. This measure has
been shown to predict poorer performance on the 24 month
Bayley Psychomotor Developmental Index and cerebral palsy at 2
years [38,39], as well a with school readiness and behavior
problems and IQ at age 4 to 4.5 years [40], suggesting potential
predictive value of these measures and DNA methylation of
HSD11B2.
Though not statistically significant, it is of interest that
HSD11B2 methylation correlated positively with infant attention
scores. Our sample size was smaller for this component, as
calculation of the attention summary score requires a minimum
number of items, which may not be collected during every
assessment [41]. Nonetheless, this observation, may suggest that
reduced expression of HSD11B2, and subsequently fetal exposure
to maternal cortisol may condition appropriate neurodevelop-
ment. Alternatively, enhanced infant attention may predict an
inability to block out stimulation and thus placing these children at
risk for over-stimulation and distraction [42]. Further studies using
larger populations are needed to better model what may be a
complex relationship between these factors.
This study is unique in its focus on a healthy, near term
population of infants from uncomplicated pregnancies. The
hypothesis, that the placenta plays a critical role in determining
downstream neurobehavioral is novel. This study represents one of
the first to link growth, epigenetic alterations of placental genes,
and early life neurobehavioral outcomes in a human population.
Our findings associate growth to epigenetic alterations of the
HSD11B2 gene, which is central to HPA axis development, and in
turn correlate these epigenetic alterations to altered infant
neurobehavioral development suggesting this is a critical pathway
for fetal programming and may play a role in neurobehavioral
health throughout life. Like all human studies, we are limited in
our ability to conclusively define the mechanism linking the
intrauterine environment to epigenetic modulation and in turn
infant quality of movement, but these studies provide impetus for
further work in model systems where such mechanisms can be
ascertained using controlled studies. Along those lines, we also
cannot demonstrate the causality of growth on methylation of
HSD11B2 and its effect on infant quality of movement, and our
power is limited to examine how growth may be altering the
association between HSD11B2 methylation and infant quality of
movement. Expansion of these studies with larger samples sizes
would be necessary to identify this effect modification. Future
studies examining additional genes and pathways central to these
outcomes are also needed and can provide novel markers for risk
thereby allowing for earlier intervention and more successful
treatment.
Methods
Study Population
Study subjects are part of the ongoing Rhode Island Child
Health Study, which enrolls mother-infant pairs following delivery
at Women and Infants Hospital of Rhode Island. Term infants
Table 2. Generalized Linear Models of the Association
between HSD11B2 Methylation Extent and Maternal and
Infant Characteristics Controlled for Confounders.
Characteristics
Estimate
(Standard Error) P
Infant Birthweight (per kg)
a 20.023 0.04
Infant Gestational Age (per week)
b 20.014 0.01
Infant Ponderal Index (per g/cm
36100)
a 20.04 0.03
Infant Length (per cm)
c 0.005 0.2
Growth Category
a
Small for Gestational Age 0.01 0.3
Appropriate for Gestational Age Referent
Large for Gestational Age 20.02 0.2
Clinically Diagnosed Intrauterine Growth
Restriction
a
Non-IUGR Referent
IUGR 0.04 0.04
Note: Each characteristic was modeled as the independent variable associated
with log-transformed HSD11B2 Methylation extent as the dependent variable.
Models controlled for
ainfant gestational age, gender, and maternal age;
bgender and maternal age;
cbirthweight, gestational age, gender, and maternal age.
doi:10.1371/journal.pone.0033794.t002
Table 3. Bivariate Correlations Between HSD11B2 Mean
Methylation Extent and NICU Network Neurobehavioral Scales
Summary Scores.
NNNS Summary Score N
Spearman Correlation
Coefficient with HSD11B2
Methylation P
Habituation 97 0.11 0.3
Attention 159 0.14 0.08
Stress Abstinence 185 0.06 0.4
Quality of Movement 185 20.18 0.01
Excitability 185 0.02 0.8
Handling 185 20.05 0.5
Self-regulation 184 20.01 0.9
Arousal 185 20.02 0.8
Hypertonicity 185 20.11 0.06
Hypotonicity 185 20.06 0.4
Asymmetrical Reflexes 185 20.07 0.3
Lethargy 185 20.06 0.5
Non-optimal Reflexes 185 20.02 0.7
doi:10.1371/journal.pone.0033794.t003
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th percentile), or
large for gestational age (LGA, highest 10
th percentile), based on
birthweight and gestational age and calculated from the Fenton
growth chart [43], are selected; infants appropriate for gestational
age (AGA) matched on gender, gestational age (63 days), and
maternal age (62 years) are also enrolled. Only singleton, viable
Figure 3. Plots of the relationships of HSD11B2 mean methylation and selected NICU Network Neurobehavioral Scales. Scatterplots of
the correlations between HSD11B2 mean methylation extent (x-axis) and infant NICU Network Neurobehavioral Scales (A) Quality of Movement, (B)
Attention, and (C) Hypertonicity scores (y-axes). Values of the Spearman correlation coefficient (r ) and its P-value are presented with each plot.
doi:10.1371/journal.pone.0033794.g003
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maternal age,18 years or a life-threatening medical complication
of the mother, and congenital or chromosomal abnormality of the
infant. A structured chart review was used to collect information
from the maternal inpatient medical record from delivery, and
mothers were subjected to an interviewer-administered structured
questionnaire to obtain information on the lifestyle, demographics,
and exposure histories of the participants. The NICU Network
Neurobehavioral Scales (NNNS) examination was administered
during the newborn inpatient stay, prior to discharge by certified
psychometrists, who were blinded to the study hypothesis. The
NNNS is a comprehensive evaluation of the neurobehavioral
performance of high-risk term and preterm infants, that includes
neurological and behavioral measures and signs of stress [44].
Items for the NNNS were scored by using previously established
summary scores [40]. For this analysis, 185 subjects, the first
participants with NNNS data enrolled between September 2009
and September 2010, were examined. All subjects provided
written informed consent for participation under appropriate
protocols approved by the Institutional Review Boards for Women
and Infants’ Hospital and Brown University.
Placenta Sample Collection, Nucleic Acid Extraction and
Bisulfite Modification
For each subject and within 2 hours of delivery, 12 samples of
placenta tissue, 3 from each of 4 quadrants (totaling approximately
1 g of tissue) were excised. All samples were taken from the
maternal side of the placenta, 2 cm from the umbilical cord
insertion site, free of maternal decidua. The samples were placed
immediately in RNAlater and stored at 4uC. At least 72 hours
later, placenta samples were removed from RNAlater, blotted dry,
snap-frozen in liquid nitrogen, homogenized using a mortar and
pestle, and stored in sample tubes at 280uC until needed for
examination. DNA was extracted from the placenta samples using
the QIAmp DNA Mini Kit (Qiagen, Inc.), and RNA was extracted
using the RNeasy mini kit (Qiagen) following manufacturer’s
protocols. Purified DNA and RNA were quantified using a ND-
1000 spectrophotometer (Nanodrop, Wilmington, DE), and DNA
Table 4. Generalized Linear Models of the Association between HSD11B2 Methylation Extent and NICU Network Neurobehavioral
Scales Quality of Movement, Attention, and Hypertonicity Scales.
Unadjusted Adjusted
Estimate (Standard Error) P Estimate (Standard Error) P
Quality of Movement
Log HSD11B2 Mean Methylation Extent 21.29 (0.58) 0.03 21.18 (0.58) 0.04
Infant Growth Status
Small for Gestational Age – 20.08 (0.12) 0.5
Appropriate for Gestational Age – Referent
Large for Gestational Age – 0.04 (0.14) 0.8
Infant Gender
Female – Referent
Male – 0.03 (0.10) 0.7
Maternal Age (yrs) – 0.02 (0.01) 0.01
Attention
Log HSD11B2 Mean Methylation Extent 1.89 (1.1) 0.09 1.56 (1.13) 0.17
Infant Growth Status
Small for Gestational Age – 20.15 (0.23) 0.5
Appropriate for Gestational Age – Referent 0.2
Large for Gestational Age – 20.36 (0.28)
Infant Gender
Female – Referent
Male – 20.24 (0.20) 0.2
Maternal Age (yrs) – 20.002 (0.02) 0.9
Hypertonicity
Log HSD11B2 Mean Methylation Extent 20.92 (0.61) 0.13 20.69 (0.61) 0.3
Infant Growth Status
Small for Gestational Age – 0.06 (0.12) 0.6
Appropriate for Gestational Age – Referent
Large for Gestational Age – 0.51 (0.14) 0.0005
Infant Gender
Female – Referent
Male – 20.07 (0.11) 0.5
Maternal Age (yrs) – 20.010 (0.010) 0.3
doi:10.1371/journal.pone.0033794.t004
HSD11B2 Methylation, Growth and Neurobehavior
PLoS ONE | www.plosone.org 7 March 2012 | Volume 7 | Issue 3 | e33794samples (1 mg) were bisulfite-modified using the EZ DNA
Methylation Kit (Zymo Research, CA, USA.) and stored at
220uC. RNA samples were aliquoted and stored at 280uC and
samples were thawed only once for expression analysis.
Bisulfite pyrosequencing DNA methylation analysis
Pyrosequencing was performed on PCR product amplified from
bisulfite-modified DNA as described previously based on the region
sequenced and displaying differential methylation in human placenta
from Alikhani-Koopaei et. al [18]. In brief, HotStar Taq DNA
Polymerase (Qiagen) and the following forward and biotinylated
reverse primers were used for amplification: HSD11B2-F, 59-
GGAAGTGGGGTTGTGYGTTTTTAGGTTTAAGTT -39 and
HSD11B2-R, 59-biotin-ATACCCTTTACTAATCRCACCACC-
39 (IDT Inc., Coralville, IA). Cycling conditions were 94uCf o r
15 minutes followed by 45 cycles of 94uCf o r3 0s e c o n d s ,5 5 uCf o r
1m i n u t ea n d7 2 uC for 1 minute with a final extension of 7 minutes
at 72uC. PCR products were sequenced using a PyroMark MD
system and the following sequencing primer (IDT): HSD11B2-seq,
59-GGGGTAGAGATTTTAAGAA -39. The sequencing primer
was designed to sequence four CpG sites, and the dispensation orders
for the assays was GTCGATGTCAGTCGTTAGTTCGTA. The
percent methylation at each CpG site was quantified using the Pyro
Q-CpG software, version 1.0.9. (Qiagen). In order for a sample’s
methylation extent to be called, it must exhibit at leasta 93% bisulfite
conversion rate, as assessed by pyrosequencing, and all samples
examined exhibited a rate .95%. To prevent batch effects from
bisulfite treatments interfering with the analysis, samples were
randomized across batches.
Gene Expression
Expression of the HSD11B2 mRNA was measured using
commercially available Taqman Gene Expression Assays (Applied
Biosystems, Valencia, CA) on an Applied Biosystems 7500 Real
Time PCR system and analyzed with 7500 System Software. All
reactions were run in triplicate, with GAPDH serving as a referent.
A pooled sample of RNAs from placentas not used in this study
was run on each plate and served as a reference sample to allow
normalization using the DDCt method.
Statistical Analysis
The mean extent of methylation across all 4 CpG sites was
utilized in all analyses. Correlation between mean methylation and
the log-transformed normalized gene expression was assessed
using non-parametric Spearman rank correlation analysis. As the
extent of methylation was skewed and not normally distributed,
bivariate associations between continuous infant and maternal
characteristics or NICU Network Neurobehavioral Scales Sum-
mary Scores and log-transformed methylation were assessed using
a Spearman correlation, while bivariate associations between
categorical characteristics and log-transformed methylation extent
were examined using nonparametric Mann-Whitney U or
Kruskal-Wallis Tests, as appropriate. Generalized linear models
were used to model associations between methylation extent and
infant characteristics or NICU Network Neurobehavioral Scales
Summary Scores controlled for confounders. To satisfy the
underlying assumptions of a linear model, a log10 transformation
was applied to methylation extent in order to approximate a
normal distribution. Final models of infant quality of movement,
attention scores, and hypertonicity and HSD11B2 methylation
included infant growth status (SGA, AGA, LGA), infant gender,
and maternal age. We also examined models including maternal
tobacco use and insurance as a marker of socioeconomic status,
but these factors showed no significant association and did not
alter the effect estimates of the other factors, and so were not
considered confounders and for parsimony were removed from the
models. Data were analyzed in R.
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